| Stage | MSA | % of rev | PSA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $536M | 100.00% | $1.4B | 100.00% | PSA ×2.55 |
| Gross profit | $244M | 45.53% | $989M | 72.41% | PSA +26.9pp |
| Operating income | $88M | 16.45% | $317M | 23.20% | PSA +6.8pp |
| Pre-tax income | $82M | 15.28% | $363M | 26.59% | PSA +11.3pp |
| Net income | $58M | 10.89% | $378M | 27.69% | PSA +16.8pp |
| Stage | MSA | PSA | Gap · A − B |
|---|---|---|---|
| Revenue | $536M100.00% | $1.4B100.00% | PSA ×2.55 |
| Gross profit | 45.53%$244M | 72.41%$989M | PSA +26.9pp |
| Operating income | 16.45%$88M | 23.20%$317M | PSA +6.8pp |
| Pre-tax income | 15.28%$82M | 26.59%$363M | PSA +11.3pp |
| Net income |
| 10.89%$58M |
| 27.69%$378M |
| PSA +16.8pp |
No disclosed counterparties: PSA.
None